[HTML][HTML] Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Abstract Purpose In 2017, the Geneva Alzheimer's disease (AD) strategic biomarker
roadmap initiative proposed a framework of the systematic validation AD biomarkers to …
roadmap initiative proposed a framework of the systematic validation AD biomarkers to …
Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution
Recent advances in chemical, molecular, and genetic approaches have provided us with an
unprecedented capacity to identify drug-target interactions across the whole proteome and …
unprecedented capacity to identify drug-target interactions across the whole proteome and …
First tau PET tracer approved: toward accurate in vivo diagnosis of Alzheimer disease
H Barthel - Journal of Nuclear Medicine, 2020 - Soc Nuclear Med
On May 28, the Food and Drug Administration approved 18F-flortaucipir, also known as
AV1451, under the trademark name Tauvid (Avid Radiopharmaceuticals), for estimation of …
AV1451, under the trademark name Tauvid (Avid Radiopharmaceuticals), for estimation of …
[HTML][HTML] The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community
On June 7th, 2021, for the first time since 2003, a novel drug against Alzheimer's disease
(AD), aducanumab (Aduhelm™), has been approved in the USA by the Food and Drug …
(AD), aducanumab (Aduhelm™), has been approved in the USA by the Food and Drug …
α-synuclein PET and Parkinson disease therapeutic trials: ever the twain shall meet?
JP Seibyl - Journal of Nuclear Medicine, 2022 - Soc Nuclear Med
Neurodegenerative disorders are common brain afflictions with increasing prevalence in
countries with aging populations. This is true for the two most common neurodegenerative …
countries with aging populations. This is true for the two most common neurodegenerative …
Imaging biomarkers for central nervous system drug development and future clinical utility: lessons from neurodegenerative disorders
JP Seibyl - Journal of Nuclear Medicine, 2023 - Soc Nuclear Med
Diseases of the central nervous system are common and often chronic conditions
associated with significant morbidity. In particular, neurodegenerative disorders including …
associated with significant morbidity. In particular, neurodegenerative disorders including …
Amyloid imaging in dementia and neurodegenerative disease
MR Ponisio, P Iranpour, TLS Benzinger - Hybrid PET/MR Neuroimaging: A …, 2022 - Springer
Alzheimer's disease (AD) accounts for 70% of dementia cases. Neuropsychological testing
has limited sensitivity and specificity compared with the gold standard of histological …
has limited sensitivity and specificity compared with the gold standard of histological …
Investigating Imaging Biomarkers in Normal Ageing and Cognitive Impairment
L Prosser - 2024 - discovery.ucl.ac.uk
All features of Alzheimer's disease (AD), from symptom development, copathologies, and
atrophy patterns, are heterogeneous. AD related biomarkers should be considered for their …
atrophy patterns, are heterogeneous. AD related biomarkers should be considered for their …
Imaging in drug development
O Carmichael - Atkinson's Principles of Clinical Pharmacology, 2022 - Elsevier
New, more efficient drug discovery paradigms could fundamentally allow evaluation of a
greater number of targets, many of which today have only preclinical face validity, and …
greater number of targets, many of which today have only preclinical face validity, and …